EnteroBiotix has completed enrolment for its investigator‑initiated phase 2a MAST trial, which is evaluating the company’s microbiome therapy EBX‑102‑02 in adults undergoing allogeneic haematopoietic stem cell transplantation for defined haematological malignancies.
The study, sponsored by Imperial College London and funded by the Medical Research Council, has recruited 50 patients across leading UK transplant centres. Participants receive either EBX‑102‑02 or a matched placebo before conditioning chemotherapy and will be followed for 12 months after transplant.
The trial aims to address the profound disruption to the gut microbiome commonly seen during transplantation. Loss of microbial diversity has been linked with higher risks of infection, graft‑versus‑host disease and reduced survival.
MAST will investigate whether a single pre‑emptive oral dose of EBX‑102‑02 can help preserve microbial diversity during this vulnerable period, with exploratory outcomes assessing clinical transplant measures. Topline data are expected in H1 2027.
Professor Julian Marchesi explained: “Profound disruption of the intestinal microbiome is common during allogeneic stem cell transplantation and has been strongly associated with adverse outcomes.
“MAST builds on prior promising work from the Imperial team utilising traditional FMT approaches and has been designed to assess whether pre‑emptive microbiota restoration using EBX‑102‑02 can preserve microbiome diversity during the transplant period and potentially improve post‑transplant outcomes. We are pleased to have completed enrolment and thank the patients and clinical teams involved.”
Dr James McIlroy, Chief Executive Officer of EnteroBiotix, said: “Completion of enrolment in MAST builds on our recent progress in IBS and cirrhosis and marks another step in evaluating the potential of EBX‑102‑02 across multiple indications with high unmet medical need.
“We are excited about the potential of our platform and technology for supporting the treatment of oncology patients. We thank the Imperial investigators for their collaboration and look forward to topline data in H1 2027.”
